Marina Biotech this week announced that its stock has begun trading on the over-the-counter markets after the company was unable to meet the Nasdaq's listing requirements.

"I and our board of directors have decided, at this point, that the company is not in a position to meet the listing standards of the Nasdaq stock market,” Marina President and CEO Michael French said in a statement. “By utilizing the strengths of the OTC markets, we believe we can be in a position in the future to return to a national securities exchange if we so choose."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.